Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2019

View Archived Issues

New inhibitor blocks, degrades MYC

Study identifies metabolic path from stress to anxiety

Antisense oligonucleotides inhibit nonsense-mediated RNA decay in W1282X cystic fibrosis

AVEO Oncology and Biodesix initiate CyFi-2 study of ficlatuzumab plus high-dose cytarabine

EIP Pharma releases data from the REVERSE-SD study of neflamapimod

Mologen announces the initiation of phase IIa TITAN combination trial

Positive topline data from phase III VANISH-303 registration study of oral ibrexafungerp

Voclosporin DDI study demonstrates no clinically significant interaction with MMF

Discovery and preclinical characterization of a novel anti-CD178 antibody, FBP-002

Antisense therapy with antagomiR-23b shows promise for the treatment of DM1

Novel nonhuman primate model of induced colitis

Psioxus Therapeutics presents series of oncolytic viral compounds for cancer

Recombinant human thrombomodulin evaluated for ARDS with disseminated intravascular coagulation

Merck KGaA starts phase III study of L-praziquantel orodispersible in Schistosoma-infected children

Novel gene therapy for the treatment of Alzheimer's disease

AAV encoding NUsc1 rescues memory in Alzheimer's disease model

Supernus Pharmaceuticals provides data from phase III P301 study of SPN-810

Researchers divulge new compounds for malaria

Masitinib reduces severe asthma exacerbation rate in phase III study

Constellation Pharmaceuticals patents EZH2 inhibitors

Merck & Co. synthesizes new IDO1 inhibitors

The Medicines discloses new boronic acid-based antibacterials

C4 Therapeutics discovers new cereblon ligands for cancer

Targeting acquired immunity improves brain injury recovery

Affimed's IND for AFM-24 cleared for phase I/II study in EGFR-expressing cancers

AvantGen enters collaboration to use NK cell engager platform to generate anticancer therapeutics

Promising phase I data presented for the mutant-selective KRAS G12C inhibitor MRTX-849